Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022
Reunion continues to hold a 21.84% interest in FTHW.
- Reunion continues to hold a 21.84% interest in FTHW.
- Reunion is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds.
- Although the management of believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect.
- Neither Toronto Stock Exchange, or its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.